Evotec (EVO) secured two new grants from the Gates Foundation for tuberculosis drug discovery and development, the company said Thursday.
The funding will support expansion of novel tuberculosis drug candidates and help advance selected drug combinations toward clinical evaluation, the company said.
The first grant will focus on developing novel small molecule therapies using its artificial intelligence-enabled drug discovery platform, while the second grant will support nonclinical evaluation of next-generation drug combinations, including long-acting injectables.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments